NCT04819100 A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT04782076 A Drug Drug Interaction (DDI) Study of Selpercatinib and Dabigatran in Healthy Participants Status COMPLETED Phase PHASE1
NCT04759911 Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT04591431 The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT04320888 Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT04280081 A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT04268550 Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial) Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT04211337 A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT04194944 A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT03944772 Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD) Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT03906331 Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation Status APPROVED_FOR_MARKETING Phase N/A
NCT03899792 A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors Status ACTIVE_NOT_RECRUITING Phase PHASE1/PHASE2
NCT03155620 Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) Status ACTIVE_NOT_RECRUITING Phase PHASE2